Ryvu Therapeutics completed construction in June of 2020 on the R&D Center for Innovative Drugs in Krakow, Poland. Accommodating approximately 300 employees, the $20 million headquarters and research facility will enable the clinical-stage biopharmaceutical company to accelerate the development of novel small molecule therapies that address emerging targets in oncology. The six-story, 108,000-sf structure includes offices, technical suites, social areas, and 32,300 sf of lab space for medicinal chemistry, biochemistry, analytical chemistry, and cell and molecular biology.